TABLE 3 Pharmacological interventions tested in dogs with cognitive decline. Name/type Mode of action Testing in dog Results/outcomes References LY2886721 BACE1 inhibitor Pharmacology study in dogs and clinical trial in healthy volunteers Aβ lowering in plasma and CSF May et al.,2015 Selegiline (L-deprenyl) MAOB inhibitor Longitudinal study Higher life expectancy (cognitive status not monitored) Ruehl et al.,1997 Selegiline (L-deprenyl) MAOB inhibitor Performance studies Improved visuospatial working memory (in only a subset of dogs) Head et al., 1996; Campbell et al., 2001; Studzinski et al.,2005 Atorvastatin Reduction of Aβ and BACE1 Longitudinal study Neuroprotective Barone et al.,2012 Adrafinil A wakefulness-promoting agent (eugeroic) with nootropic effects Longitudinal study; pharmacological study A significant increase in locomotion; improved learning; impaired working memory Siwak et al., 2000; Studzinski et al.,2005 Ampakine Positive modulator of AMPA receptors (enhance excitatory glutamatergic neurotransmission) Pharmacological study Decrease of performance accuracy; may have memory impairing effects Studzinski et al.,2005 CP-118,954 Acetylcholinesterase inhibitor Pharmacological study Minimal cognitive enhancing effects Studzinski et al.,2005 Phenserine Acetylcholinesterase inhibitor Pharmacological study; performance study Enhancing effects on memory and learning; improved performance (only in a subset of dogs treated) Studzinski et al., 2005; Araujo et al.,2011a Donepezil Acetylcholinesterase inhibitor Performance study memory enhancement Araujo et al.,2011a CNP520 BACE1 inhibitor Dogs, human Safe to use in dogs; tolerated in healthy humans; ongoing clinical trials Neumann et al.,2018 Antioxidant-rich diet with cognitive enrichment / Dogs Improved cognition Opii et al., 2008; Dowling and Head,2012 Anti-Aβ immunotherapy Passive vaccination with injections of antibodies against Aβ42 Dogs Reduced amyloid plaques and reduced astrogliosis Head et al., 2008; Neus Bosch et al., 2015; Davis et al.,2017